Abstract
The heterogeneity and resistance of chronic myelogenous leukemia in blastic phase (CML-BP) are attributed to: (1) the involvement of the earliest progenitor cell by the disease ptocess and (2) the acquisition of multiple mutational events during the evolution from the chronic to the blastic phase.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
